📣 𝗦𝗲𝗹𝗲𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝗗𝗶𝗮𝗹𝘆𝘀𝗶𝘀 & 𝗥𝗲𝗹𝗮𝘁𝗲𝗱 𝗝𝗼𝘂𝗿𝗻𝗮𝗹 𝗔𝗿𝘁𝗶𝗰𝗹𝗲 𝗔𝗹𝗲𝗿𝘁𝘀 Week 40 (29-Sep – 05-Oct) What’s new in dialysis research publication during the past week? Roxadustat represents a viable alternative to ESA for renal anaemia management (1). By the next decade, future KRT interventions has the opportunity to offer truly individualized care (2). High dialysate sodium concentrations potentially causes acute endothelial injury, highlighting the importance of managing sodium levels during HD to minimize vascular injury (3). Residual kidney creatinine clearance can be estimated in patients receiving one or two dialysis treatments weekly based on creatinine kinetic modelling (4). Detailed travel recommendations for hemodialysis and peritoneal dialysis patients to minimize the associated travel risks (5). Evaluating the (short-term) clinical safety and efficacy and performance of SAPD treatment in a small group of stable adult PD patients in a clinical setting: A proof of concept: (6). 1) Comparative Effectiveness and Safety of Roxadustat versus Erythropoiesis-Stimulating Agents in Patients Receiving Maintenance Hemodialysis: A Real-World Cohort Study, 𝘒𝘪𝘥𝘯𝘦𝘺 𝘋𝘪𝘴𝘦𝘢𝘴𝘦𝘴, 𝘈𝘥𝘷𝘢𝘯𝘤𝘦𝘥 𝘗𝘶𝘣𝘭𝘪𝘤𝘢𝘵𝘪𝘰𝘯, 𝘚𝘦𝘱𝘵𝘦𝘮𝘣𝘦𝘳 29, 2025, (Open Access): https://lnkd.in/dqtXau2H 2) Beyond Diffusion: Harnessing Physical Principles for Precision Kidney Replacement Therapy, 𝘊𝘑𝘈𝘚𝘕, 𝘈𝘥𝘷𝘢𝘯𝘤𝘦𝘥 𝘗𝘶𝘣𝘭𝘪𝘤𝘢𝘵𝘪𝘰𝘯, 𝘖𝘤𝘵𝘰𝘣𝘦𝘳 01, 2025, (Open Access): https://lnkd.in/ddYpBagh 3) The Effect of Dialysate Sodium on Endothelial Injury and Microcirculatory Dysfunction, 𝘒𝘪𝘥𝘯𝘦𝘺360, 𝘌𝘢𝘳𝘭𝘺𝘈𝘤𝘤𝘦𝘴𝘴, 𝘖𝘤𝘵𝘰𝘣𝘦𝘳 3, 2025, (Open Access): https://lnkd.in/dREdy-py 4) Creatinine Kinetic Modeling to Estimate Residual Kidney Creatinine Clearance in Patients Being Hemodialyzed Once or Twice Per Week, 𝘚𝘦𝘮𝘪𝘯 𝘋𝘪𝘢𝘭, 𝘌𝘢𝘳𝘭𝘺𝘈𝘤𝘤𝘦𝘴𝘴, 𝘖𝘤𝘵𝘰𝘣𝘦𝘳 03, 2025, (Open Access): https://lnkd.in/dPCz9BaY 5) From Dialysis to Destinations: Safe Travel Strategies for Patients with CKD, 𝘒𝘐 𝘙𝘦𝘱𝘰𝘳𝘵𝘴, 𝘈𝘳𝘵𝘪𝘤𝘭𝘦𝘐𝘯𝘗𝘳𝘦𝘴𝘴, 𝘖𝘤𝘵𝘰𝘣𝘦𝘳 04, 2025, (Open Access): https://lnkd.in/d4jgECwV 6) Rationale and design of the CORDIAL first-in-human clinical trial: A system for sorbent-assisted continuous flow peritoneal dialysis, 𝘗𝘋𝘐, 𝘖𝘯𝘭𝘪𝘯𝘦𝘍𝘪𝘳𝘴𝘵, 𝘚𝘦𝘱𝘵𝘦𝘮𝘣𝘦𝘳 26, 2025, (Open Access): https://lnkd.in/d8TgYFys Image: Innovations in dialysis research Source: AI generated image #kidneycare #chronickidneydisease #ckd #hemodialysis #peritonealdialysis #roxadustat #anaemia #diffusion #convection #dialysate #sodium #endothelialinjury #creatinine #residualkidneyfunction

Chronic Kidney Disease Market — Overview, Recent Opportunities, Growth Size, Regional Analysis & Forecasts 2024–2034 To Know More : https://lnkd.in/dTrgGWyY Chronic Kidney Disease Market is projected to expand significantly from $52.9 billion in 2024 to $102.8 billion by 2034, reflecting a CAGR of 6.9%. The growth of this market is driven by the rising global prevalence of CKD, the increasing aging population, and the growing burden of diabetes and hypertension — two of the most common risk factors for kidney disease. The CKD market encompasses a broad range of products and services including pharmaceuticals, dialysis equipment, renal replacement therapies, and diagnostic tools, all aimed at improving patient outcomes and quality of life. With advancements in medical technology and the introduction of innovative biologics, the CKD landscape is evolving rapidly. The dialysis segment continues to dominate, with hemodialysis being the most widely adopted treatment due to its proven efficacy and accessibility. Peritoneal dialysis, on the other hand, is gaining traction for offering flexibility and enabling home-based care. In the pharmaceuticals domain, erythropoiesis-stimulating agents remain essential for managing anemia in CKD patients, while phosphate binders play a critical role in addressing mineral and bone disorders associated with kidney dysfunction. #ckdmarket #kidneyhealth #medicalinnovation #healthcareindustry #chronicdisease #pharmamarket #medicalresearch #nephrology #marketgrowth #futureofhealthcare

𝗦𝗲𝗹𝗲𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝗗𝗶𝗮𝗹𝘆𝘀𝗶𝘀 & 𝗥𝗲𝗹𝗮𝘁𝗲𝗱 𝗝𝗼𝘂𝗿𝗻𝗮𝗹 𝗔𝗿𝘁𝗶𝗰𝗹𝗲 𝗔𝗹𝗲𝗿𝘁𝘀 Roxadustat represents a viable alternative to ESA for renal anaemia management 1). By the next decade, future KRT interventions has the opportunity to offer truly individualized care (2). High dialysate sodium concentrations potentially causes acute endothelial injury, highlighting the importance of managing sodium levels during HD to minimize vascular injury (3). Residual kidney creatinine clearance can be estimated in patients receiving one or two dialysis treatments weekly based on creatinine kinetic modelling (4). Detailed travel recommendations for hemodialysis and peritoneal dialysis patients to minimize the associated travel risks (5). Evaluating the (short-term) clinical safety and efficacy and performance of SAPD treatment in a small group of stable adult PD patients in a clinical setting: A proof of concept: ( 6). 1) Comparative Effectiveness and Safety of Roxadustat versus Erythropoiesis-Stimulating Agents in Patients Receiving Maintenance Hemodialysis: A Real-World Cohort Study, 𝘒𝘪𝘥𝘯𝘦𝘺 𝘋𝘪𝘴𝘦𝘢𝘴𝘦𝘴, 𝘈𝘥𝘷𝘢𝘯𝘤𝘦𝘥 𝘗𝘶𝘣𝘭𝘪𝘤𝘢𝘵𝘪𝘰𝘯, 𝘚𝘦𝘱𝘵𝘦𝘮𝘣𝘦𝘳 29, 2025, (Open Access): https://lnkd.in/dqtXau2H 2) Beyond Diffusion: Harnessing Physical Principles for Precision Kidney Replacement Therapy, 𝘊𝘑𝘈𝘚𝘕, 𝘈𝘥𝘷𝘢𝘯𝘤𝘦𝘥 𝘗𝘶𝘣𝘭𝘪𝘤𝘢𝘵𝘪𝘰𝘯, 𝘖𝘤𝘵𝘰𝘣𝘦𝘳 01, 2025, (Open Access): https://lnkd.in/ddYpBagh 3) The Effect of Dialysate Sodium on Endothelial Injury and Microcirculatory Dysfunction, 𝘒𝘪𝘥𝘯𝘦𝘺360, 𝘌𝘢𝘳𝘭𝘺𝘈𝘤𝘤𝘦𝘴𝘴, 𝘖𝘤𝘵𝘰𝘣𝘦𝘳 3, 2025, (Open Access): https://lnkd.in/dREdy-py 4) Creatinine Kinetic Modeling to Estimate Residual Kidney Creatinine Clearance in Patients Being Hemodialyzed Once or Twice Per Week, 𝘚𝘦𝘮𝘪𝘯 𝘋𝘪𝘢𝘭, 𝘌𝘢𝘳𝘭𝘺𝘈𝘤𝘤𝘦𝘴𝘴, 𝘖𝘤𝘵𝘰𝘣𝘦𝘳 03, 2025, (Open Access): https://lnkd.in/dPCz9BaY 5) From Dialysis to Destinations: Safe Travel Strategies for Patients with CKD, 𝘒𝘐 𝘙𝘦𝘱𝘰𝘳𝘵𝘴, 𝘈𝘳𝘵𝘪𝘤𝘭𝘦𝘐𝘯𝘗𝘳𝘦𝘴𝘴, 𝘖𝘤𝘵𝘰𝘣𝘦𝘳 04, 2025, (Open Access): https://lnkd.in/d4jgECwV 6) Rationale and design of the CORDIAL first-in-human clinical trial: A system for sorbent-assisted continuous flow peritoneal dialysis, 𝘗𝘋𝘐, 𝘖𝘯𝘭𝘪𝘯𝘦𝘍𝘪𝘳𝘴𝘵, 𝘚𝘦𝘱𝘵𝘦𝘮𝘣𝘦𝘳 26, 2025, (Open Access): https://lnkd.in/d8TgYFys

Exciting News in Nephrology: Semaglutide Demonstrates Safety for Patients on Dialysis Recent data presented at the EASD 2025 Annual Meeting highlights an important advancement for patients receiving kidney dialysis. For the first time, a large prospective cohort analysis shows that the GLP-1 receptor agonist semaglutide is safe in this population, with no significant increase in serious adverse cardiovascular events or mortality compared to placebo. 🔍 Study Overview: 34,064 patients from major trials (SUSTAIN-6, SELECT, FLOW, SOUL) were analyzed. Out of 307 participants who initiated dialysis during the study, 50% on semaglutide and 56% on placebo continued medication post-dialysis initiation. Follow-up of 1.15 years after dialysis start confirmed similar rates of cardiac, infection, and GI adverse events—and even suggested a numerically lower MACE and mortality rate with semaglutide. 📈 Clinical Implications: This is the largest prospective study of its kind in dialysis patients receiving incretin therapy. The findings reinforce that semaglutide could be a safe therapeutic option for individuals at high cardiovascular risk on dialysis. Further research is warranted to explore its full benefit on outcomes in this setting. 🧠 Key Takeaway: “Treatment with semaglutide was not associated with a higher proportion of serious adverse events—including MACE and all-cause mortality—among those initiating dialysis. We also noted a potential benefit for cardiovascular and mortality outcomes.” —Dr. Klara R. Klein, UNC Chapel Hill Let’s celebrate these new insights and look forward to more evidence for improving outcomes in this vulnerable patient group! #Nephrology #Dialysis #Semaglutide #GLP1 #Diabetes #Cardiovascular #EASD2025 #PatientSafety #MedicalResearch

The recent Nature Medicine article introduces a novel evidence-based treatment algorithm for obesity and its complications, as outlined by the European Association for the Study of Obesity (EASO). https://lnkd.in/dRnhNfkB Key Novelty This framework distinguishes obesity as both a fat mass disease and a sick fat disease, guiding pharmacological approaches according to patient-specific health backgrounds rather than focusing solely on weight loss. It features a comprehensive synthesis of published randomized controlled trials up to January 2025, resulting in tailored recommendations for first-line treatments based on complication profiles, with drugs such as tirzepatide and semaglutide leading for substantial weight loss and specific comorbidities. Impact on Clinical Care The EASO algorithm empowers clinicians to offer personalized, holistic care for obesity, optimizing therapy selection based on efficacy for weight loss and direct benefits on obesity-driven complications like sleep apnea, knee osteoarthritis, diabetes, cardiovascular disease, heart failure, and metabolic liver disease. This marks a shift away from a “one-size-fits-all” approach, enabling more precise, safe, and effective patient management, and aligning treatment goals to personal values and clinical needs. Forward-Looking Perspective The article underscores the need for ongoing updates as new evidence emerges, keeping treatment recommendations current in this rapidly evolving field. By integrating economic considerations and the growing recognition of obesity’s multifactorial nature, it sets the stage for broader healthcare reforms and improved patient outcomes. This publication will shape future obesity management by establishing a cutting-edge, patient-centered framework for pharmacological intervention.

𝐈𝐬 𝐢𝐦𝐩𝐫𝐨𝐯𝐞𝐦𝐞𝐧𝐭 𝐨𝐟 𝐌𝐀𝐒𝐇 𝐚𝐧𝐝 𝐟𝐢𝐛𝐫𝐨𝐬𝐢𝐬 𝐚𝐟𝐭𝐞𝐫 𝐭𝐢𝐫𝐳𝐞𝐩𝐚𝐭𝐢𝐝𝐞 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐢𝐧 𝐒𝐘𝐍𝐄𝐑𝐆𝐘-𝐍𝐀𝐒𝐇 𝐓𝐫𝐢𝐚𝐥 𝐫𝐞𝐥𝐚𝐭𝐞𝐝 𝐭𝐨 𝐦𝐞𝐭𝐚𝐛𝐨𝐥𝐢𝐜 𝐚𝐧𝐝 𝐰𝐞𝐢𝐠𝐡𝐭 𝐫𝐞𝐝𝐮𝐜𝐭𝐢𝐨𝐧 𝐩𝐚𝐫𝐚𝐦𝐞𝐭𝐞𝐫𝐬? Interesting paper entitled "Relationship Between Metabolic and Histological Responses in People With Metabolic Dysfunction-Associated Steatohepatitis With and Without Type 2 Diabetes: Participant-Level Exploratory Analysis of the SYNERGY-NASH Trial With Tirzepatide" just published in Diabetes Care by CYRIELLE CAUSSY and colleagues. https://lnkd.in/eDbVB_-W ✍Authors aimed to explore the relationship between metabolic and histological responses in a phase 2 trial of tirzepatide in metabolic dysfunction–associated steatohepatitis (MASH). ✍This is a participant-level post hoc analysis of the 52-week, double-blind, randomized, placebo-controlled SYNERGY-NASH trial. Participants (n = 190) with MASH and stage 2/3 fibrosis were randomly assigned to receive tirzepatide (5, 10, or 15 mg) or placebo once weekly. ✍The primary end point was MASH resolution without worsening of fibrosis. Secondary end points included fibrosis improvement by at least one stage without worsening of MASH. ✍At baseline, 59% had type 2 diabetes and mean BMI was 35.7 kg/m2. Compared with nonresponders, greater body weight reductions were observed in responders for MASH resolution (−16.0% vs. −7.0%; P < 0.001) and for fibrosis improvement (−13.6% vs. −9.8%; P = 0.023). ✍Reductions in HbA1c were greater for MASH responders (−1.2% vs. −0.6%; P < 0.001) and fibrosis responders (−1.2% vs. −0.7%; P = 0.004) than for nonresponders. ✍Compared with nonresponders, greater improvements in liver fat and measures of adipose tissue insulin sensitivity (adipose tissue insulin resistance index and adiponectin) were observed with MASH responders (P < 0.001). ✍In causal mediation analyses, normalization of liver fat was a significant mediator of both MASH resolution and fibrosis improvement. 🤓 GLP-1, GLP-1/GIP and GLP-1/glucagon agonists are very promising candidates for the treatment of MASH with 2.4 semaglutide already having completed phase 3 trial 🤓It is always important to explore the exact mechanims 🤓This exloratary analysis show a strong relationship between weight reducing efficacy of tirzepatide and its influenceMASH resolution and fibrosis improvement. 🤓Additional important mechanism could be antiinflammatory effect

“Compared with nonresponders, greater improvements in liver fat and measures of adipose tissue insulin sensitivity (adipose tissue insulin resistance index and adiponectin) were observed with MASH responders (P < 0.001). In causal mediation analyses, normalization of liver fat was a significant mediator of both MASH resolution and fibrosis improvement.”

𝗙𝗢𝗥𝗘𝗣𝗔𝗦𝗦® 𝗗𝗘𝗟𝗜𝗩𝗘𝗥𝗦 𝟴𝗫 𝗪𝗘𝗜𝗚𝗛𝗧 𝗔𝗡𝗗 𝟮𝗫 𝗗𝗜𝗔𝗕𝗘𝗧𝗘𝗦 𝗢𝗨𝗧𝗖𝗢𝗠𝗘𝗦 𝗩𝗦 $𝟮𝟴𝗕/𝗬𝗘𝗔𝗥 𝗦𝗘𝗠𝗔𝗚𝗟𝗨𝗧𝗜𝗗𝗘 Landmark large-animal results vs Semaglutide (Ozempic/Wegovy), the standard of care. Published in the leading journal 𝘋𝘪𝘢𝘣𝘦𝘵𝘦𝘴, 𝘖𝘣𝘦𝘴𝘪𝘵𝘺 𝘢𝘯𝘥 𝘔𝘦𝘵𝘢𝘣𝘰𝘭𝘪𝘴𝘮: • 8x greater effect on weight • 2x greater improvement in insulin sensitivity • Zero incisions, fully reversible, 30-minute endoscopic placement For the 50M+ patients with BMI ≥35 + diabetes in the U.S. and 5 largest European countries, the clinical threshold for reversing disease is ~30% weight loss. 92% of patients on Semaglutide fail to reach even 15%. ForePass® is the first non-surgical option in history to approach surgical-level outcomes. • Prof. Geltrude Mingrone (Obesity & Diabetes Guidelines): “A defining moment: ForePass replicates the effects of bariatric surgery, substantially surpassing medication.” • David Feigal (former FDA Director): “The single most important innovation in severe obesity and diabetes treatment.” 📘 Peer-reviewed Publication: https://lnkd.in/e4p-dH3S 📄 Press Release: https://lnkd.in/eZmCJy4N Acknowledgment: Prof. Marco Castagneto, Dr Ivo Boskoski, and Dr Manoel Galvao Neto for their critical contributions toward the development of ForePass®. #Diabetes #Metabolism #Obesity #Medtech #Innovation

Encouraging preclinical results from Keyron Medical Technology, where the ForePass® device showed greater improvements in metabolic parameters than once-weekly semaglutide in a controlled large-animal study. While based on a limited number of animals, these data provide early support for exploring non-pharmacologic, mechanism-based approaches to obesity and metabolic disease. As a board member, I’m proud of the team’s dedication and steady progress toward redefining the future of metabolic health. #Obesity #MetabolicHealth #GLP1 #Innovation #MedicalDevices #Keyron #ForePass